@article{e571ab44079c4ce9aa02b99293e946e6,
title = "Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis",
keywords = "Amyotrophic Lateral Sclerosis/blood, Anti-Bacterial Agents/adverse effects, Ceftriaxone/adverse effects, Demography, Female, Follow-Up Studies, Humans, Male, Middle Aged, Research Design",
author = "Berry, \{James D.\} and Shefner, \{Jeremy M.\} and Robin Conwit and David Schoenfeld and Myles Keroack and Donna Felsenstein and Lisa Krivickas and David, \{William S.\} and Francine Vriesendorp and Alan Pestronk and Caress, \{James B.\} and Jonathan Katz and Ericka Simpson and Jeffrey Rosenfeld and Robert Pascuzzi and Jonathan Glass and Kourosh Rezania and Rothstein, \{Jeffrey D.\} and Greenblatt, \{David J.\} and Cudkowicz, \{Merit E.\}",
note = "Funding Information: JDB has served as a consultant to Biogen Idec and as a paid speaker for Oakstone Publishing. He receives research report from the Muscular Dystrophy Association and ALS Therapy Alliance. JMS has served as a consultant to Biogen Idec, Cytokinetics, Trophos, ISIS, Glaxo Smith Kline, and receives research support from the Muscular Dystrophy Association, ALS Association, ALS Therapy Alliance, Cytokinetics, Biogen Idec, Sanofi Aventis, Neuraltus. RC is employed at the National Institute of Neurological Disorders and Stroke. DS, over the last 24 months, has served as a biostatistical consultant to Averion, Inc, Gerson Lehrman Group, Guidepoint Global, Neuronova, Cytokinetics, Glaxo Smith Kline, Merck, Aggennix, Pfizer, Biogen Idec, and Elan. He has received research support from AstraZeneca, Roche, CytRx, and ISIS. MK has no relevant disclosures to report. DF has received research funds from Euroimmune, Allere, Focus, Biokit, BioRad and Diasorin, Chronic Fatigue Initiative. LK has no relevant disclosures to report. WSD has no relevant disclosures to report. FV has no relevant disclosures to report. AP receives revenue related to antibody patent licenses from Athena; owns stock in Johnson \& Johnson; directs the Washington University Neuromuscular Clinical Laboratory which performs antibody testing; and receives research support from the National Institutes of Health, Muscular Dystrophy Association, Neuromuscular Research Fund, Insmed, Knopp, Cytokinetics, Biogen Idec, ISIS, Genzyme, GSK, Ultragenyx \& Sanofi. JBC has no relevant disclosures to report. JK has no relevant disclosures to report. ES has no relevant disclosures to report. JR has served on scientific advisory boards and/or as a consultant for Hill-ROM Inc, Cytokinetics and Avanir Pharmaceuticals. RP has no relevant disclosures to report. JG receives research support from the Muscular Dystrophy Association and from the National Institute of Neurological Disorders and Stroke. KR has no relevant disclosures to report. JR has research funding from National Institutes of Health, Department of Defense, P2ALS, Muscular Dystrophy Association, Robert Packard Center for ALS Research at Johns Hopkins. He has acted as a consultant to Biogen Idec, Cytokinetics and Psyadon Pharmaceuticals, Inc. DJG has no relevant disclosures to report. MEC served on DSMB for Synapse and Trophos and was a consultant for TEVA, Millenium, GlaxoSmithKline and Biogen. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. ",
year = "2013",
month = apr,
day = "17",
doi = "10.1371/journal.pone.0061177",
language = "English",
volume = "8",
journal = "PLoS ONE",
issn = "1932-6203",
number = "4",
}